Under the partnership, AMRA’s MRI Body Composition Profiling and expertise in metabolic diseases, musculoskeletal conditions and muscle wasting will be combined with Micron’s existing reach in Japan’s imaging research markets.
AMRA CEO Eric Converse said: “We are very happy to have Micron as a partner for the second largest medical market. A local partner in the sophisticated Japanese market is necessary and will mean better service to domestic clients.”
Micron is said to have the biggest medical imaging analysis team in Japan. Its logistical organisation and expertise will be used to support the launch of AMRA’s technology in Japanese clinical trials.
Micron president Michita Sato said: “Micron has a corporate mission that Micron is committed to human health and medical progression by supporting research activities in the medical field through utilising imaging technologies.
“To introduce AMRA’s technology into Japan definitely matches this mission and we believe it will bring an innovative step for the researches of pharmaceuticals and academics. AMRA has a unique capability that uses AI with high precision and in 3D quantify the whole muscles and fat in rapid MRI scans.”
AMRA Global Business Development and Marketing senior vice-president Rosemary Shull said: “Japanese pharmaceutical companies and academic researchers show great interest in AMRA’s digital health solutions and with this partnership, we can expect increased business and strengthen our relationships in Japan”
Founded in 2010, AMRA produces muscle and fat biomarkers and deliver disease insights from a single, rapid, whole-body MRI.